Exhaled nitric oxide after beta2-agonist inhalation and spirometry in asthma

Area of Science:

• Respiratory Medicine
• Clinical Measurement
• Biomarkers

Background:

• Exhaled nitric oxide (ENO) is a valuable marker for airway inflammation.
• Standard clinical assessments like spirometry and bronchodilator use are common in respiratory research.
• The potential impact of these standard procedures on ENO measurements is not fully understood.

Purpose of the Study:

• To investigate the acute effects of spirometry and bronchodilator administration on exhaled nitric oxide levels.
• To determine the temporal recovery of ENO levels after these interventions.
• To provide recommendations for controlling confounding factors in respiratory research.

Main Methods:

• ENO was measured before and serially for 1 hour after spirometry in healthy volunteers and mild asthmatic subjects.
• In asthmatic subjects, ENO was also measured after salbutamol or placebo inhaler administration.
• Statistical analysis was performed to assess significant changes in ENO.

Main Results:

• Spirometry caused an immediate and transient decrease in ENO levels in both healthy and asthmatic subjects.
• ENO levels returned to baseline within 1 hour post-spirometry.
• Salbutamol administration in asthmatic subjects led to a significant increase in ENO levels compared to placebo.

Conclusions:

• Spirometry and beta2-agonist (salbutamol) administration can transiently alter exhaled nitric oxide measurements.
• These findings highlight the need to control for spirometry and bronchodilator use when interpreting ENO data.
• Recommendations are made for study design to mitigate these potential confounding effects on airway inflammation assessment.